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A B S T R A C T
Invasive cervical cancer is second most common female cancer worldwide with about 493 000 new cases per year.
About 273 000 women die from cervical cancer each year, 85% of which take place in developing countries. Cervical can-
cer has a slow progress, from pre-invasive cervical intraepithelial neoplasia (CIN) to invasive phases, meaning that the
disease can be diagnosed while in the phase of pre-invasive lesion, and treated successfully thanks to the regular screen-
ing of asymptomatic women (the Pap smear). The authors review new possibilities of early detection of cervical cancer
with emphasis on colposcopy. The role of colposcopy is discussed among possibilities of early diagnosis. The authors dis-
cuss additional diagnostic procedures for preinvasive lesions of the uterine cervix like DNA cytometry, (flow cytometry).
This method can point to dysplasia which can progress to severe stages, such as HSIL (High grade Squamous Intra-
epithelial Lesion). If the level of chromosomal disturbance is higher (aneuploidy), it is more probable that HSIL will de-
velop. Laser screening of cells extracted with modern cytologic screening LBC (Liquid Base Cytology) enables us to auto-
matically measure ploidy (chromosome regularity, or irregularity) and PCR provides analysis of HPV types. These methods
are recommended for a routine check-up of borderline cervical lesions in order to anticipate ones likely to regress or progress.
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Introduction
According to the 2003 yearbook, 313 new cases of cer-
vical cancer (13.7/100000) and 493 cases of Cervical
Intraepithelial Neoplasia (CIS) in Croatia were disco-
vered1. Although the cervical cancer mortality rate is on
the decrease, 100 women still die every year1. Cervical
cancer is second most common female cancer worldwide
with about 493 000 new cases per year, and it is most
common female cancer in Africa, Asia and South Ame-
rica2. About 273 000 women die from cervical cancer each
year, 85% of which take place in developing countries2.
There were 12 800 new cases and 4 600 fatal outcomes in
the US during the year 2000. Mean age of cervical cancer
patients is 51.4 years, with an almost equal distribution
in age groups 30 to 39 years and 60 to 69 years3. In
Croatia, in the age groups between 25–39 years and
50–64 years, a decreasing trend of cervical cancer inci-
dence is observed. An increase of cervical cancer inci-
dence over the last 20 years has been observed in the
age-groups 40–44 and 45–49 years4.
Cervical cancer has a slow progress, from pre-invasive
intraepithelial neoplasia (CIN) to invasive phases, which
means that the disease can be diagnosed while in the
phase of pre-invasive lesion, and treated successfully
thanks to the regular screening of asymptomatic women
(the Pap smear).
In developed countries, most cases of cervical cancer
are diagnosed among women without the regular Pap
smear. Unfortunately, in developing countries, the scree-
ning of asymptomatic women is often not available.
In addition to this sad fact, attitudes towards this dis-
ease and the lack of public health education make the sit-
uation even worse.
This is the population in which we can find patients
with cervical cancer in advanced phases, when the dis-
ease has spread into the bladder, the rectum, the nerve
pathways of the pelvis, or the bone.
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Radiotherapy and palliative care are often insuffi-
cient in these countries, so many patients die as outcasts,
suffering from extreme pain and bearing the stench of
the vaginal secretion. These are mostly women who have
children who still depend on them, so their deaths cause
severe dysfunctions in the family.
Cervical Cancer Symptoms
Abnormal vaginal bleeding is the most common symp-
tom of invasive cervical cancer. Among sexually active
women, the symptoms include postcoital bleeding, al-
though one must not dismiss both the intermenstrual
and the postmenopausal bleedings.
In comparison with endometrial cancer, which is ra-
ther quickly manifested by bleeding, cervical cancer among
women who are not sexually active is asymptomatic until
it reaches an advanced stage.
The large tumor mass is often infected, so there is a
stench vaginal discharge present, even prior to vaginal
bleeding.
Pretorius and colleagues5 report that in advanced
stages of the disease the first signs can be the following:
pelvic pain; pressure – that is tenderness in rectal or
bladder regions; occasional discharge of urine or faeces
through vagina. The report includes 81 patients with the
diagnosis of cervical cancer: 56% of them had vaginal
bleeding as the first symptom of the disease, 28% had an
abnormal Pap smear, 9% suffered from pain, 4% had vag-
inal discharge, and 4% had no symptoms.
It should be mentioned that small tumors, meaning
the earlier stages of the disease, were found among pa-
tients with an abnormal Pap smear.
Diagnostic Procedures
Making an early diagnosis of cervical cancer can pres-
ent a challenge for the following reasons:
a) its frequent asymptomatic nature,
b) if there is no possibility of a gynaecological examina-
tion in speculas for distinguishing the source of the
disease in the endocervical canal or under the ecto-
cervical epithelia,
c) because of a fairly high percentage of false-negative
Pap smear results, even among regular patients.
Gynecologic Examination in Cervical
Cancer Diagnosing
In speculas the primary lesion is seen as: exophytic
(Figure 1), endophytic, ulcerative, or polipoid. If the tu-
mor is growing under the epithelium or in the endocer-
vical canal, ectocervix can seem intact macroscopically.
The direct spread into the vagina is visible, but the infil-
tration can be subepithelial and possible only with oblit-
erated vaginal vaults or the presence of cervical stenosis.
In later stages the visualization of the cervix can be
difficult. During manual palpation, the cervix feels indu-
rated (except in pregnancy), and enlarged.
The size of the cervix can best be measured by rectal
examination, which is necessary to estimate the spread
of the disease on the parametrium, as well. MRI helps us
get more precise information on the spread of the disease
and thus the stage of the disease. Additional physical ex-
amination must include: the palpation of the liver, of the
supraclavicular and inguinal lymph nodes, in order to
rule out metastatic disease.
Complementary contemporary radiology techniques
in the assessment of cervical volume as well as the ultra-
sound diagnostics must be taken in mind.
Tissue sampling for patohistological verification is an
inevitable part of diagnostic protocol. Any tumor mass or
ulceration calls for histological analysis, in this case for
the so-called punch biopsy (excisio probatoria cervicis).
Any unusually indurated or enlarged cervix needs to be
analysed through biopsy and/or endocervical abrasion.
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Fig. 1. Invasive cervical cancer.
TABLE 1
SUGGESTED PROTOCOL ON THE TREATMENT OF PATIENTS
WITH THE ABNORMAL PAP SMEAR DEPENDING ON THE
COLPOSCOPIC FINDING
Satisfactory finding Unsatisfactory finding
Minor change • Control for 6 month
• Repeat PAP smear
• HPV test
• Control colposcopy
Major change • Biopsy + PHD • Biopsy + PHD
IC suspected • Biopsy + PHD • Biopsy + PHD
Both satisfactory and unsatisfactory colposcopic findings deal with
thorough visibility of the uterine portio, SCJ- squamocolumnar
Cytological Test in Diagnosing Cervical
Cancer
Cytological diagnosis of conventional cervicovaginal
smear or Pap test is one of the most efficient screening
tests known to date, which has been credited with the
significant decline in the incidence and mortality of cer-
vical carcinoma in the world. The measures of cervical
cytology availability as a screening test are its sensitivity,
specificity, predictive value and diagnostic accuracy. The
sensitivity of cervical screening in Croatia is 90.0%, spec-
ificity 98.6%, positive predictive value 92.3%, negative
predictive value 98.1% and overall diagnostic accuracy
97.2%6. The main objection to conventional cytology as a
screening test refers to its low sensitivity, false positive
and false negative results. In the last few decades new
techniques of cervical cytology sampling and processing
such as liquid-based cytology (LBC), have been devel-
oped. The advantages of LBC over conventional smear
are reduced rate of inadequate samples and false nega-
tive findings, higher rate of abnormal cytology findings
detected and significantly shorter time needed for analy-
sis of a specimen prepared by LBC method6.
Human Papillomavirus Testing
There are clear benefits for the use of HPV DNA test-
ing in the triage of equivocal smears, low-grade smears in
older women and in the post-treatment surveillance of
women after treatment for CIN7. However, there are still
issues regarding how best to use HPV DNA testing in
primary screening. Primary screening with Hybrid Cap-
ture((R)) 2 (HC2) generally detects more than 90% of all
CIN2, CIN3 or cancer cases, and is 25% relatively more
sensitive than cytology at a cut-off of abnormal squ-
amous cells of undetermined significance (ASC-US) (or
low-grade squamous intraepithelial lesions (LSIL) if ASC-
-US unavailable), but is 6% relatively less specific7. In
countries where cytology is of good quality, the most at-
tractive option for primary screening is to use HPV DNA
testing as the sole screening modality with cytology re-
served for triage of HPV-positive women. Established cy-
tology-based programmes should also be gradually moving
towards a greater use of HPV DNA testing to improve
their efficacy and safely lengthen the screening interval.
The greater sensitivity of HPV DNA testing compared to
cytology argues strongly for using HPV DNA testing as
the primary screening test in newly implemented pro-
grammes, except where resources are extremely limited
and only programmes based on visual inspection are
affordable7.
The Role of Colposcopy
Colposcopy is necessary if the gynecologist finds no
unusual features of the cervix in the patient with symp-
toms or an abnormal Pap smear. On the other side if a
firm diagnosis cannot be set after the biopsy, diagnostic
cone biopsy is recommended. Colposcopic detection of
microinvasive cancer depends on its size and location
(Figure 2). The gynaecologist can miss smaller lesions,
although the probability of stromal invasion increases
with the level of lesion spread on the surface. If the
microinvasive cancer is entirely within the endocervical
canal, the ectocervix can seem alright during colposcopy.
Signs of microcancers of the ectocervix are atypical blood
vessels prone to bleeding.
Atypical blood vessels are located unusually and ran-
domly, they differ in diameter, and often change direc-
tion, forming sharp angles. Intercapillary distance is
larger and changeable (Figure 2).
The colposcopy enlarges the picture of the early inva-
sive cancer and shows the surface and the atypical blood
vessels. In these cases of IA1–IB1 thorough colposcopy
may enable to find scribble shaped border between ill
uterine cervix and rather health vaginal coupole tissue.
It is important in planning the size of upper third vaginal
tissue involvement in radical hysterectomy removal, thus
leaving middle and lower third of the vaginal tissue
health and able to bring endovaginal irradiation source
when needed.
Endophytic tumors often look like erosions. When en-
larged, papillary surface and atypical blood vessels are
visible. Keratosis can mask the colposcopical finding of
an underlying lesion, which is the reason why biopsy is
necessary. Due to our colposcopic experience uterine cer-
vix adenocarcinoma has no distinctive features. We can
spot all vascular changes that have been described so far.
Histology
In the presence of a satisfactory examination, colpo-
scopically directed punch biopsy becomes the gold stan-
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Fig. 2. Microinvasive cervical cancer.
dard of diagnosis. All women with a smear showing high
grade Squamous Intraepithelial Lesion (HSIL) should
have material submitted for histology. Women with a
smear showing Low grade Squamous Intraepithelial Le-
sion (LSIL) and who have no abnormalities detected by
colposcopy should have repeat smear preformed; if it is
normal, it is safe to follow-up citologically. In low grade
SIL (LSIL) immature basal type cells occupy lower third
of the epithelium. Histological abnormalities associated
with LSIL are a result of proliferation of basal and
parabasal cells in the infected epithelium8. The resultant
hyperplasia can be highly variable and take many forms
but is most commonly characterized by papillomatosis
and acanthosis. In high grade SIL (HSIL) immature
basal-type cells occupy more than the lower third of the
epithelium. In addition there is nuclear crowding, pleo-
morphism and loss of the normal cell polarity8.
Flow Cytometry
Additional diagnostic procedure for preinvasive le-
sions of the uterine cervix is DNA cytometry, (flow cyto-
metry). This method can point to dysplasia which can
progress to severe stages, such as HSIL (High grade
Squamous Intraepithelial Lesion). If the level of chromo-
somal disturbance is higher (aneuploidity), it is more
probable that HSIL will develop.
Laser screening of cells extracted with modern cyto-
logic screening (LBC) enables us to automatically mea-
sure ploidity (chromosome regularity or irregularity) and
PCR analysis of HPV types. These methods are recom-
mended for a routine check-up of borderline cervical le-
sions in order to anticipate ones likely to regress or prog-
ress. DNA cytometry of targeted excision samples from
sites selected by colposcopy presents a challenge.
Here is a common dilemma: the claim of the expert
clinician that CIN ll is biologically closer to dysplasia le-
vis (CIN l) and that it requires no aggressive approach,
and the answer that this is only possible after the neo-
plastic potential of the lesion is confirmed by flow cyto-
metry technique. It is only after this procedure that we
can decide on the follow-up or ablation techniques!
Until this becomes the practice, we are left with cyto-
logical analysis, which is to be made two months after the
biopsy (biopsy forceps, or diathermic loop), which is de-
scribed in the protocol for premalignant lesions9,10.
On the basis of the follow-up cytological analysis, re-
peated colposcopies and complete revisions tell us what
to do next.
Basic Directives
Colposcopy classifications and achievements varied
from Graz 1975 to Barcelona 2002 as follows:
Graz classification11 stated that aceto-white epithe-
lium makes an abnormal colposcopic finding, Rome classi-
fication12 stated that such epithelium is almost patogno-
monic for HPV infection, and can be more or less visible,
with or without clear borders, while Barcelona classi-
fication13 points out all of the above including the state-
ment that aceto-whitening can appear quickly and slowly
disappear, or slowly appear and disappear quickly. This is
related to the intensity of the disruption of intracellular
chromatine in HPV infected cells.
Colposcopic classification which points to normal and
abnormal colposcopic images of various stages of abnor-
mality and availability of transformation zone is comple-
mented by cytological classification14 and patohistolo-
gical classification8.
These are the prerequisites for the collaboration of
the gynaecologist, the cytologist and the pathologist, in
order to achieve the best results through establishing
protocols for diagnostics and treatment.
Protocol for diagnostics and treatment of premalig-
nant lesions of the cervix and lower genital tract is a cor-
ner stone we hadn’t had and which was created from
1996 to 2000, and at last established at the conference
celebrating 75 years of colposcopy in clinical practice in
Croatia.
The protocol has become a landmark for all of us who
delved into the comprehensive subject of preinvasive cer-
vical lesions9,10. At clinical training courses in colposcopy
and early diagnostics and prevention of neoplastic chan-
ges in the lower genital tract the theoretical practice
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TABLE 2
EXISTING PROTOCOL ON TREATMENT OF PATIENTS WITH ABDORMAL PAP SMEAR AND UNSATISFACTORY COLPOSCOPIC FINDING
OR WITH MICROINVASCIVE CARCINOMA OF SQUAMOS CELLS ON PROBATORI EXCISION
Status of the excision of microinvasion
up to 5 mm or less
Recommendations
Margins clear, ECC negative, stage IA1
with no spread to lymphovascular area:
• cone biopsy if the patient wants to preserve fertility
Margins and/or ECC positive dysplasia
• repeat cone biopsy
• modified radical hysterectomy
• if conization not appropriate, then perform hysterectomy +/– pelvic lymphadenectomy
Stage IA1 with invasion into
lymphovascular area
• pelvic lymphadenectomy + conisation, or radical trachelectomy (for fertility reasons)
• modified radical hysterectomy and pelvic lymphadenectomy
Adopted from Hacker, 200016, ECC/endocervical curretage, LVSI – lympho vascular space invasion
ends with the protocol, and then we present a series of
colposcopic images in order to entice discussion on possi-
ble gravity of lesions and patohistological verification.
Our great interest in the issue led us to the introduc-
tion of those ablation and destruction procedures which
will spare the cervix and hence the reproductive system
of our patients, and their health as a whole.
The cytologic and colposcopic protocol that we estab-
lished for the follow-up after classic probatory excision
by forceps (Kevorkian, Thomas Gaylor) or after proba-
tory excision by loop decreases the number of unneces-
sary cold knife cones and diathermic cones by loop.
In cases of persistent cytologic abnormalities, after bi-
opsy, and a second colposcopic examination, it could be
easier to decide on one of such procedures in order to pre-
serve the gynaecological and reproductive health.
We must point out that is necessary to inform the pa-
tient that diathermic cone biopsy (LETZ) and classic
cone biopsy with scalpel did remove the site of a poten-
tially more severe change, but at the same time we must
point that the responsibility lies both in the hands of the
woman and her partner, in order to ensure that such sit-
uation does not repeat in the future.
What if the Disease Progresses?
The collaboration of the gynaecologist, the cytologist,
and the pathologist implies that the current state of a pa-
tient needs to be discussed on several levels: the stage of
the initial invasion, the sample on which the initial inva-
sion was discovered, age and parity of the patient. After
we consider these levels, we can decide on further treat-
ment of the patient.
Common Questions in Colposcopic Practice
The earlier the cervical cancer is diagnosed, the better
the chances are of successful treatment. Here are some
basic issues in our everyday clinical, and gynaecological
and oncological practice. I will also take into consider-
ation those patients in advanced stages of this disease.
A) The approach to the treatment of microinvasive pla-
nocellular cervical cancer IA1 diagnosed after LETZ
biopsy or classic test excision by forceps. What if the
patient is a nulliparous, or if she had a baby once, or
more times?
B) The approach to the treatment of microinvasive pla-
nocellular cervical cancer IA2 diagnosed after LETZ
biopsy or after classic test excision by forceps. What if
the patient is a nulliparous, or if she had a baby once,
or more times?
C) The approach to the treatment of microinvasive pla-
nocellular cervical cancer IA1 diagnosed after LETZ
biopsy or after classic cone biopsy by scalpel. What if
the patient is a nulliparous, or if she had a baby once,
or more times?
D) The approach to the treatment of microinvasive pla-
nocellular cervical cancer IA2 diagnosed after LETZ
cone biopsy or after classic cone biopsy by scalpel.
What if the patient is a nulliparous, or if she had a
baby once, or more times?
What about the grey area? How to treat patients with
stromal invasion of more than 5 mm, the spread larger
than 7 mm, and the change still not visible to the naked
eye? Do they already belong to the IB1 group or not?
What about reproduction? What if the finding is an inci-
dental finding at hysterectomy, or at a diagnostic cone bi-
opsy, or at one of the mentioned excohleation of the cervi-
cal canal or probatory excisions?
All of the above requires thorough studying taking in
mind FIGO classification as the most acceptable for all
those involved in cervical cancer diagnosis and trea-
tment15 (Figure 3).
Importance of Continuous Medical
Education
Colposcopic diagnostic accuracy depends upon a prac-
titioner’s proficiency. Therefore, not only a well struc-
tured initial training but also a continuous practice with
proper clinical feedback is necessary. The European col-
poscopy training programs in 2004 reached the consen-
sus on a structure of a program. It is recognized that
training must involve actual colposcopic experience that
is supervised by a trainer in a recognized centre. The
trainer and the experience received must meet certain
standards in terms of workload and case-mix. It has been
agreed that in EFC-recognized training programs train-
ees would see a minimum of 100 patients17.
Multidisciplinary Approach to Cervical
Cancer Prevention
Cervical cancer prevention strategies should be di-
rected from secondary to primary prevention. Two pro-
phylactic human papillomavirus (HPV) vaccines have
been shown to be highly effective and are now recom-
mended for use in many countries. As a result, primary
prevention of cervical cancers that are attributable to
HPV types 16 and 18 is now possible. Although this has
been enthusiastically embraced, it brings new challen-
ges. Other aspect of a primary prevention is education in
sexually responsible behavior. Considering the lowering
age of first sexual intercourse one should make every ef-
fort to establish multidisciplinary teams (physicians, psy-
chologists, teachers…) and appropriate settings for such
an education.
Conclusion
Numerous questions and answers were brought up
during the postgraduate clinical training course »Diag-
nostics, Treatment and Prognosis for Preinvasive Le-
sions and Carcinoma of the Cervix« held at the Ob/Gyn
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Clinic in University clinical center Zagreb, on 7 and 8
April 2006.
Critical scientific and practical thinking and the par-
ticipation of gynaecologists, pathologists, cytologists, ra-
diologists and epidemiologists established firm founda-
tions for a comprehensive insight into this issue.
The foundations created leeway both for experts and
young colleagues in these areas of medicine to work on
setting up national programs for cervical cancer screening.
Necessary collaboration among complementary spe-
cialties, consulting with more experienced colleagues and
regular publication of results will improve women s
gynecologic health care. Due to Consensus18 we also
point out the following recommendations:
1. Colposcopy allows identification, localization and de-
lineation of premalignat lesions of the cervix, vagina
and vulva and directs the biopsy site.
2. In some countries, colposcopy is used as a screening
tool but because of its low specificity, it should not be
used in primary screening but reserved for those
women who have been shown to have abnormal cervi-
cal cytology.
3. Colposcopy must be preformed prior to treatment of
cervical intraepithelial neoplasia.
4. Colposcopy should be preformed only by trained and
experienced colposcopist. Colposcopists should audit
their work to confirm that the outcome of their colpo-
scopic assessment and colposcopically-directed treatment
is keeping up with internationally agreed standards.
5. The colposcopic findings should be recorded in pa-
tient’s charts.
We hope that above mentioned statements will enable
a better insight and therapeutic outcome of this group of
gynecologic patients.
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DIJAGNOSTI^KI PRISTUP PREKANCEROZAMA I RANOM INVAZIVNOM RAKU VRATA
MATERNICE
S A @ E T A K
Invazivni rak vrata maternice je jedan od naj~e{}ih uzroka smrti od malignih ginekolo{kih bolesti, sa oko 493 000
novootkrivenih slu~ajeva u svijetu godi{nje. Rak vrata maternice napreduje sporo, od preinvazivne intraepitelne neo-
plazije (CIN) do invazivne faze, {to zna~i da se mo`e na vrijeme sprije~iti sa redovitim testovima probira (PAPA test). U
ovome ~lanku iznosimo pregled novijih dostignu}a u ranoj detekciji raka vrata maternice s posebnim naglaskom na
mjesto i ulogu kolposkopije i njenih dosega, ali i ograni~enja. Predla`emo da u svim dostupnim stanjima mikroinvazije i
rane invazije neoplasti~nog procesa vrata maternice kolposkopski pregledamo i vrat maternice i svodove rodnice, a u
svrhu mogu}eg odre|ivanja koju {irinu vaginalne man`ete uklju~iti kod radikalne histerektomije i tako prevenirati
mogu}i recidiv.
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